





- I Germinal Matrix Bleed
- II Ventricular Bleed
- III Ventricular Bleed + dilation of ventricle
- IV Parenchymal bleed








Mortality



### Neurologic Sequelae


#### Grade I/II IVH


- No increased risk for major disability.
- Grade III IVH
  - ~30% with major disability at school age most common are spastic diplegia and quadriplegia.
  - Cognitive and neuromotor disability common, ~50% require special education.
- Grade IV IVH
- Little data b/c  $\downarrow$  frequency  $\uparrow$  mortality.
- 80% manifest symptoms of major disability during infancy.
- Most common: contralateral hemiparesis; cognitive and neuromotor ability affected.








- Grade III ~20%
- Grade IV >60%
- Inflammation, clot, protein and debris results in ventricular obstruction and then progressive and rapid accumulation of CSF.
- Severe ventricular dilation increases intracranial pressure and destroys surrounding parenchyma.
- TX with serial spinal taps or VP shunt.


























### Prognosis

- Bowel Surgery:
  - Resection
  - Long-term parenteral nutrition
  - Enterostomy care, short gut syndrome, failure to thrive
- NEC with perforation: 20-40% mortality
- Uncomplicated Course:
  - Growth, nutrition, GI function appear to catch up by the end of the first year



- The zone of ROP describes the location.
- The stage of ROP describes how far along in this progression the vessels have reached. Concerns <u>></u>Stage 4 ROP.







- Preemies born <1500g or <28wks
- Any severely ill preemie
- Any preemie with prolonged oxygen therapy
- Then, exams every 2 weeks or more often until discharge
- Follow-up post discharge:
  - Regressed ROP without scars: until full vascularization then annually
  - Regressed ROP with scars: annually
  - Progressed ROP (detachment): ongoing care



## **ROP: Treatment**

- Based on results of the ETROP study, treatment is recommended for any eye with:
  - Zone I any stage with plus disease,
  - Zone I, stage 3 without plus disease, or
- Zone II stage 2 or 3 with plus disease.
- Cryotherapy: Freezing of avascular retina anterior to the retina. Peak age is time of discharge.
- Laser therapy: Uses laser beam. Better tolerated, easier, faster, requires less sedation & better reaches most important area for vision (posterior retina).
- Scleral Buckle & Vitrectomy Procedures: Heroic. Some anatomic success but less functional improvement.




#### **ROP:** Common Sequelae


- Regressed without scars: strabismus, amblyopia, myopia.
- Regressed with scars: thinning of retina, retraction, retinal tears-retinal draggingdetachment-glaucoma, vision loss.
- Progressed ROP: reduced visual acuity, visual field loss, reduction in contrast sensitivity, nystagmus, glaucoma.

#### As & Bs


- Apnea: pause in breathing >20 seconds.
- Bradycardia: fall in heart rate, often accompanies breathing lapse.
- Incidence: 10% preemies, >40% VLBW.
- Treatment: theopylline or caffeine used to stimulate breathing, rocker beds.
- Persistent apnea correlated with bad prognosis:
  - May indicate brain damage.
  - May be precursor to SIDS:
    - 20% of all SIDS are preemies.
    - Occurs during first 5 months of life.
  - Babies w/ As at discharge go home on monitor.




- Surgical ligation to close the ductus.




- Severe: coughing and wheezing followed by dyspnea; severe tachypnea is common; in cases of extreme hypoxemia, respiratory failure occurs.
- In high-risk infants, respiratory failure severe enough to require airway intubation can occur early in the course of illness.







# RSV...More Facts

- RSV disease is universal and occurs in nearly all children by 2 years of age.
- RSV is the leading cause of hospitalization in infants <1 year old.
- RSV epidemics are local and local virology is the best way to determine timing of RSV prophylaxis.
- Effective therapeutic options are not available.
  Synagis<sup>®</sup> (palivizumab) is the only
- immunoprophylaxis option approved by the FDA.
- Synagis is generally well tolerated and effective in preventing hospitalizations due to severe RSV infections.







[Hussey-Gardner, B., Sulc, W., Miller, M. & Baugh, C. 2003]





#### Methods

- Retrospective reviews UMMS NICU Follow-up Clinic's database and the BITP database were conducted.
- All infants born in 1997, 1998, and 1999.
- Baltimore City residents.
- Gestational age < 37 weeks.
- Referred to UMMS' NICU Follow-up Clinic.
- 399 infants identified for study, 286 attended at least one visit, 154 followed until age 3 years.

High Probability Diagnoses					
Overall, 64.3% automatically eligible	Attend (N=286)	Never Attend (N=113)			
Birthweight (BW) < 1200g	56.9% (60)	46% (52)			
Cytomegalovirus (CMV)	1.5% (4)	0			
Congenital Anomalies	4.1% (11)	0			
Congenital Infections	1.9% (5)	1.7% (1)			
Genetic Anomalies	.4% (1)	0			
Hypoxic-Ischemic Encephalopathy (HIE)	.7% (2)	1.4% (1)			
Hydrocephalus	3.4% (9)	6.6% (4)			
Intraventricular Hemorrhage (IVH) III/IV	2.2% (6)	1.7% (1)			
Microcephaly	.4% (1)	0			
Other Brain Abnormality (e.g., PVL)	4.1% (11)	5% (3)			
Seizures	.7% (2)	1.7% (1)			
Sensory Impairment	.4% (1)	3.4% (2)			
Ventriculomegaly	.4% (1)	1.7% (1)			
Withdrawal	3.7% (10)	8.3% (5)			

Other Diagnoses					
	Attend (N=286)	Never Attend (N=113)			
Bronchopulmonary Dysplasia (BPD)	39.7% (106)	20% (12)			
Gastroesophageal Reflux (GER)	9.7% (26)	6.7% (4)			
Hypothyroidism	12.4% (33)	8.3% (5)			
Intrauterine Growth Retardation (IUGR)	2.6% (7)	3.3% (2)			
Meconium Aspiration	.7% (1)	0			
Meningitis	2.6% (7)	3.3% (2)			
Necrotizing Enterocolitis (NEC)	10.5% (28)	6.7% (4)			
Patent Ductus Arteriosus (PDA)	26.2% (70)	15% (9)			
Respiratory Distress Syndrome (RDS)	71.2% (190)	53.3% (32)			
Retinopathy of Prematurity (ROP)	27.3% (73)	23.3% (14)			
Small for Gestational Age (SGA)	4.1% (11)	13.3% (8)			
Tone Abnormal	1.5% (4)	3.4% (2)			






Diagnoses Correlated with Obtaining Specific Services						
	Any	PT	от	SI	SLP	
BPD	.254**	.182**	.194**	.186**	.162**	
Hydrocephalus	.002	.061	.124*	.129*	079	
Hypothyroidism	.152*	.045	.054	.083	.156*	
IVH	.245**	.239**	.230**	.101	.144*	
NEC	.151*	.144*	.180**	.116	.178**	
Other Brain Abnormality         .085         .089         .183**         .192**         .105						
ROP	.259**	.238**	.234**	.166**	.157**	
Seizures	.088	.122*	.061	038	053	
Tone Abnormal	.087*	.132*	.105	.041	.081	
*Significant at the .05 level. ** Significant at the .01 level.						

Diagnoses Predicting Services, Above & Beyond Birthweight						
	Any	PT	ОТ	SI	SLP	
BPD	Х		Х			
Hydrocephalus				Х		
IVH	Х	Х	Х			
NEC			Х		Х	
Other Brain Abnormality			Х	Х		
ROP		Х	Х			
Seizures		Х				
Tone Abnormal	Х	Х				
X denotes multip	le regressio	n significo	ant at p<.0	5.		

	Demographics & Diagnosis: Followed Until 3 Years				
	Yes, N=135	No, N=151			
Race	AA=93.2%	AA=87.7%			
BW	Mean=1079.8g	Mean=1348g			
	Median=956g Median=1294				
GA	Mean & Median=28wks Mean & Median=30w				
Sex	Males=48.1% Males=54%				
BPD	45.7%	34.1%			
Brain Lesion	5.5%	2.9%			
Hydrocephalus	5.4%	1.4%			
IUGR	2.3%	2.9%			
IVH	35%	21%			
ROP	36.7%	19.6%			
Tone Abnormal	3.1%	0%			

Transition at Age 3 (N=135)						
Chara	cteristic	Part B	Don't Need Services			
(Don't kno	w Part B elig N=1)	N=58, 43.9%	N=73, 55.3%			
Sex	Male	63.8%	37%			
	Female	36.2%	63%			
Race	African-American	92.9%	93.1%			
BW	Median 930 grams		989 grams			
	Mean	Mean 1086.5 grams				
	Minimum	530 grams	535 grams			
	Maximum	2505 grams	2116 grams			
GA	Median	27 weeks	27 weeks			
	Mean	28.2 weeks	28 weeks			
	Minimum	22 weeks	23 weeks			
	Maximum	36 weeks	35 weeks			

Diagnosis Correlated with Part B, Above & Beyond BW					
--	--	--	--	--	--



0	Comparison of Services						
All			BW <u>&lt;</u> 1200g		BW 1201-1500g		
	(N=	135)	(N=94)		(N=21)		
	Part <b>C</b>	Part <b>B</b>	Part C	Part <b>B</b>	Part C	Part <b>B</b>	
Any	77%	45.9%	84%	47.8%	66.7%	42.9%	
PT	51.9%	15.6%	55.3%	16.3%	42.9%	9.5%	
ОТ	34.1%	14.1%	37.2%	14.1%	23.8%	9.5%	
SI	28.9%	20%	31.9%	18.5%	9.5%	19%	
SLP	48.9%	40%	54.3%	42.4%	47.6%	38.1%	

